Skip to main content

Table 3 Multivariate analysis of PFS on pretreatment quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma

From: Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT

  HR 95%CI P
Age 1.200 0.692–2.079 0.516
Gender 0.772 0.395–1.510 0.450
Marriage 1.470 0.458–4.719 0.517
Education 1.197 0.940–1.525 0.145
Smoking history 0.951 0.518–1.747 0.872
Alcohol history 0.787 0.324–1.910 0.596
T stage 1.383 0.684–2.794 0.367
N stage 1.979 1.156–3.388 0.013
Pre-treatment EBV DNA 1.451 0.866–2.431 0.157
Post-treatment EBV DNA 3.130 1.563–6.267 0.001
Pain 1.015 0.995–1.035 0.146
Teeth 0.984 0.971–0.998 0.026
Felt ill 1.004 1.001–1.007 0.012
  1. Abbreviations: PFS Progression free survival, HR Harsard ratio